In HCC, CRISPR/Cas9 technology was used to delete IGF2BP3 in HCC cells, leading to the suppression of macrophage infiltration and M2-polarization and thus inhibiting the growth of HCC (166). This evidence concerns the gene IGF2BP3 and hepatocellular carcinoma.